Sosei Group Corporation and Kallyope announced the successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal diseases. This is the first scientific milestone stemming from the strategic drug discovery collaboration between the two companies announced in 2022. The collaboration aims to leverage Sosei Heptares' GPCR Diversified Compound Library and GPCR expertise and the innovative Kallyope Klarity(TM) platform, which combines single-cell sequencing, circuit mapping, computational biology and enteroid phenotypic screening.

The collaborating teams at Sosei Heptares and Kallyope intend to progress the nominated target into a fully supported structure-based drug discovery program as well as continuing to identify additional gastrointestinal targets for future programs.